http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Akers Biosciences Updates on Akers Wellness(TM) Tests
-
Akers Biosciences Reports Earnings for Fiscal Year 2016
-
Akers Biosciences Announces Conference Call to Discuss FY 2016 Earnings
-
Akers Biosciences to Commercialize Heparin PF4 Rapid Test in Puerto Rico
-
Akers Biosciences (AKER) Announces $2M Private Placement
-
Akers Biosciences Announces a $2 Million Private Placement
-
Akers Biosciences Reports Preliminary Unaudited Earnings Highlights for Fiscal Year 2016
-
Akers Biosciences Announces Conference Call to Discuss FY 2016 Earnings
-
Akers Biosciences (AKER) Receives Initial Order for First Check Rapid Cholesterol Test
-
Akers Biosciences Begins Selling Rapid Cholesterol Test through Distribution Agreement with First Check
-
Akers Biosciences Allowed US Patent for Akers Wellness(TM) Tests Cartridge
-
Akers Biosciences Announces Closing of Public Offering
-
Akers Biosciences (AKER) Sells ~1.67M Shares at $1.20, Plus Warrants
-
Akers Biosciences Announces Pricing of Public Offering of 1,667,000 Shares and 833,500 Warrants
-
Akers Biosciences (AKER) Enters 3-Year Deal with GNYHA for Heparin PF4 Rapid Test
-
Akers Biosciences Signs 3-year Agreement with GNYHA Services for Heparin PF4 Rapid Test
-
Cognizant Becomes Exclusive Provider of Digital Systems, Technology and Operations Services to Multiple Aker Group Industrial Portfolio Companies
-
Akers Biosciences (AKER) Signs Three Agreement with GNYHA to Introduce Heparin PF4 Rapid Test
-
Akers Biosciences Signs 3-year Agreement with Greater New York Hospital Association for Heparin PF4 Rapid Test
-
Akers Biosciences (AKER) Enters Distribution Agreement with First Check Diagnostics
-
Akers Biosciences Signs Distribution Agreement with First Check Diagnostics for Rapid Cholesterol Test
-
Akers Biosciences (AKER) Announces Completion of BreathScan DKA Trial; Results Seen as 'Highly Successful'
-
Akers Biosciences Completes Clinical Trial for Rapid Diabetic Ketoacidosis Breath Test
-
Akers Biosciences Announces Q3 Earnings
-
Akers Biosciences (AKER) Receives European Patent Covering Breath Ketone Detector
-
Akers Biosciences Issued European Patent Protection for Breath Ketone Detector
-
Akers Biosciences Announces Conference Call to Discuss Q3 2016 Earnings
-
Akers Biosciences Completes Study on First Rapid Breath Test for Oxidative Stress
-
Akers Biosciences Announces H1 and Q2 2016 Earnings
-
Akers Biosciences Announces Conference Call to Discuss Q2 2016 Earnings
-
Akers Biosciences (AKER) Completes PIFA/Chlamydia Rapid Assay Clinical Trial; Notes 'Highly Successful' Results
-
Akers Biosciences Completes Clinical Trial for Rapid Chlamydia Test
-
Akers Biosciences Signs Distribution Agreement for BreathScan OxiChek(TM)
-
Akers Biosciences to Present at LD Micro Invitational Conference
-
Akers Biosciences Reports Earnings for Q1 2016
-
Akers Biosciences Announces Conference Call to Discuss Q1 2016 Earnings
-
Akers Biosciences to Present at 'Pioneers 2016' Investor Conference
-
Akers Board Rearrangement
-
Akers Biosciences Reports Earnings for Fiscal Year 2015
-
Akers Biosciences (AKER) Announces USPTO Allowance of Heparin/PF4 Antibody Detection-Related Patent
-
Akers Biosciences Allowed US Patent for Heparin/PF4 Antibody Detection
-
Akers Biosciences Announces Conference Call to Discuss Its 2015 Earnings
-
Akers Biosciences (AKER) Receives $2.5M PIFA Heparin/PF4 Product Supply Order
-
Akers Biosciences Announces $2.5M Order to Supply PIFA Heparin/PF4 Products to China
-
Akers Biosciences Hires Leading Commercial Executives to Support Sales Growth
-
Akers Biosciences to Present at Disruptive Growth & Healthcare Conference
-
Akers Biosciences Updates on Joint Venture in China
-
Akers Biosciences to Present at 8th Annual LD Micro Investor Conference
-
Akers Biosciences Appoints Medical Technology Specialist as CEO
-
Akers Biosciences Announces Q3 2015 Earnings

